CA239-0004
Krystal-4

Phase III

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab
Plus Chemotherapy in Participants With Previously Untreated Non-squamous
Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

2024-515698-85

M24-536

Phase I/II

An Open-label Multi-Cohort Phase 1b/2 Study to Evaluate the Safety, Efficacy, and Optimal
Dose of Telisotuzumab Adizutecan in Combination With Budigalimab in Advanced or
Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease and
No Actionable Genomic Alterations

2024-514465-18  

MK1084
KANDLELIT-014

Phase II

A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as

Monotherapy and in Combination with Cetuximab, in Participants with KRAS G12C-Mutant,

Advanced Solid Tumors (KANDLELIT-014)

EU-CT-Nummer:  2025-521737-91

M25-713

AndroMETa-Lung-713

Phase II/III

A Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713

EU-CT-Nummer: 2025-521124-29

C5851005

Phase III

 Randomized, Phase 3, Open-Label Study To Evaluate Pf-08046054/SGN-PDL1V Vs Docetaxel In Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

EU-CT-Nummer: 2025-521281-97

CA266-0001
(ROSETTA Lung-201)

Phase III

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

EU-CT-Nummer: 2025-523576-23

MK-6070-003

I/II

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)

EU-CT-Nummer: 2025-521032-11